Financial & SEC Reports

Here you will find a summary of Celldex Therapeutics, Inc.'s latest financial information.

Latest 10-Q

Form	Filing date	View
10-Q	Nov 5, 2020	View HTML 0001104659-20-121786.pdf EX-101.INS - XBRL INSTANCE DOCUMENT

Latest Annual Report and 10-K

Form	Filing date	View
10-K	Mar 26, 2020	View HTML 0001047469-20-001809.pdf EX-101.INS - EX-101.INS

Latest Proxy Statement

Form	Filing date	View
DEF 14A	Apr 28, 2020	View HTML 0001047469-20-002644.pdf
DEFA14A	May 7, 2019	View HTML 0001104659-19-027504.pdf

Data provided by Kaleidoscope.

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Market Capitalization (Mil) $	704.29
Shares Outstanding (Mil)	39.57
Shares Outstanding, Average (FY) (Mil)	14.51
Float (Mil)	39.45

Investor Relations Contacts

Financial & SEC Reports

Latest 10-Q

Latest Annual Report and 10-K

Latest Proxy Statement

Share Related Items

About us

Our Pipeline